A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA’s Advocate’s Corner: March 2026
Written by Julia Thayer, Associate Director, Advocacy This month, more than 120 OCRA Advocate Leaders traveled to Washington, DC for Advocacy Day—braving snowstorms, severe weather, and even a partial government shutdown to make their voices heard on Capitol Hill. We kicked things off with a full day of training, where the group built skills, shared stories, and … Continued
OCRA’s Spring Advocacy Day Brings Impact to Capitol Hill
On March 17, 122 Advocate Leaders from nearly 40 states and Washington, DC, converged on Capitol Hill for OCRA’s Spring Advocacy Day. Together, they held 158 meetings with Congressional offices, carrying a clear message: Congress must sustain and build on its commitment to ovarian and gynecologic cancer research. The energy and reach of this year’s … Continued
Action Alert: Support Gynecologic Cancer Initiatives for FY2027
On March 17, Ovarian Cancer Research Alliance (OCRA) Advocate Leaders from across the country will be on Capitol Hill for OCRA’s Spring Advocacy Day—and we need your voice, too. If you can’t join us in person, please take action to reinforce our efforts on the Hill and help us make a big impact. Advocacy Day Priorities This … Continued